BMO Capital Downgrades Alder Biopharm (ALDR) to Market Perform Following Acquisition
Tweet
Share
E-mail
Get Alerts ALDR Hot Sheet
Price: $18.88 --0%
Rating Summary:
9 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
9 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
BMO Capital analyst Matthew Luchini downgraded Alder Biopharm (NASDAQ: ALDR) from Outperform to Market Perform after the company agreed to be acquired.
For an analyst ratings summary and ratings history on Alder Biopharm click here. For more ratings news on Alder Biopharm click here.
Shares of Alder Biopharm closed at $10.06 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Advance Auto Parts (AAP) PT Lowered to $50 at BMO Capital amid DIY Pressure
- BMO Capital Starts Semtech Corp. (SMTC) at Outperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
